Global Oral Biologics Market By Offerings (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, Combination Drugs, Others); By Therapeutic Area (Inflammatory Bowel Disease, Diabetes, Ulcerative Colitis and Crohn Disease, Acromegaly and Neuroendocrine Tumours, Osteoporosis, Inflammatory disease, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries , Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Report ID :AMI-780 | Category : Pharmaceuticals | Published Date : January, 2021 | Pages : 402 | Format :PDF